BridgeBio Pharma

BridgeBio Pharma

BridgeBio launched in 2015 under CEO Neil Kumar with backing from KKR and Viking Global Investors, built on a thesis that academically sourced, genetically validated targets were being abandoned by traditional pharma's portfolio math. The firm identifies programs aimed at diseases with clear genetic drivers — typically monogenic conditions — and creates standalone subsidiary companies for each. Each subsidiary is named after an element (Eidos, QED, PellePharm) and inherits shared functions from the parent: regulatory support, chemistry, manufacturing and controls, and executive talent. The model aims to replicate the focus of a biotech startup while maintaining the resourcing of a large-cap pharma. BridgeBio's pipeline spans cardiology, endocrinology, oncology and neurology, with a unifying focus on genetically driven diseases with measurable biomarkers. The most advanced program, acoramidis for transthyretin amyloid cardiomyopathy (ATTR-CM), achieved FDA approval as Attruby in November 2024. A second approved therapy, infigratinib for achondroplasia, received pediatric approval in 2023. Subsidiaries have partnered with external groups including Bristol Myers Squibb and Bayer for specific indications. The firm has invested across over 20 clinical-stage programs simultaneously, funding the majority from a single corporate P&L rather than traditional venture-backed subsidiary financing rounds. By late 2024, the firm's market capitalization had recovered above $5 billion after a period of clinical setbacks that tested its centralized structure. The hub employs approximately 600 professionals across research, clinical operations, and administrative functions. In November 2024, the FDA granted approval to Attruby for ATTR-CM, validating the firm's largest single program and marking a turning point in its path to sustainable revenue (per the firm's official communications, November 2024). The firm's subsidiary portfolio has included at least 15 named entities, some of which have achieved clinical validation but been wound down through consolidation upon trial failure — a Darwinian process that Kumar describes as core to the model. BridgeBio's structural differentiator is its permanent-capital approach to drug pipelines. Unlike a venture fund, which must return capital to limited partners within a fixed time horizon, BridgeBio operates as a publicly traded corporation with a single consolidated balance sheet. This allows recycling returns from successful programs back into new subsidiary formation without the fundraising friction typical of biotech venture. The structure also permits rapid redeployment of scientific talent across programs when individual subsidiaries shut down.